Ravi Ravinuthala, MD
Gastroenterology · Cincinnati, OHNPI 1669461588
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $236,341 of the $302,492 with a category attached, or 78.1%. 30 manufacturers reported payments, led by Gilead at 39.6% of the total. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 640 payments — averaging $472.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$120K
- AbbVie$68K
- Intercept Pharmaceuticals, Inc.$43K
- Madrigal Pharmaceuticals$27K
- Shionogi Inc$18K
- Ipsen Biopharmaceuticals, Inc$13K
- plus $14K from 24 others
Across 171 payments — averaging $3160.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$210K
- Gilead$127K
- Madrigal Pharmaceuticals$87K
- Intercept Pharma Europe Ltd.$48K
- Ipsen Pharma SAS$32K
- Hoffmann-la Roche Limited$21K
- plus $16K from 1 others
What the payments were for
- Consulting fees$29,31810%
- Speaking & faculty fees$236,34178%
- Travel & lodging$24,3948%
- Food & beverage$12,4404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 163 | $119,714 |
| AbbVie(2 entities) | 215 | $68,266 |
| Intercept Pharmaceuticals, Inc. | 45 | $42,864 |
| Madrigal Pharmaceuticals | 33 | $27,176 |
| Shionogi Inc | 14 | $17,900 |
| Ipsen Biopharmaceuticals, Inc | 8 | $13,067 |
| Novartis | 8 | $7,760 |
| Dova Pharmaceuticals | 6 | $3,357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $558 |
| Johnson & Johnson | 32 | $395 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $292 |
| Ironwood Pharmaceuticals, Inc | 11 | $184 |
| Medtronic | 2 | $154 |
| Lilly USA, LLC | 5 | $101 |
| Ferring Pharmaceuticals Inc. | 5 | $87 |
| QOL Medical, LLC | 4 | $81 |
| Sanofi | 3 | $67 |
| Aimmune Therapeutics, Inc. | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Celltrion USA Inc. | 3 | $57 |
| Pfizer | 3 | $51 |
| Merck | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 3 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$302,492 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 52 | $162,757 |
| RezdiffraResmetirom | 13 | $75,631 |
| LinzessLinaclotide | 57 | $51,644 |
| Ursodiol | 167 | $34,985 |
| TrulancePlecanatide | 20 | $10,863 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 39 | $6,254 |
| Dexlansoprazole DrDexlansoprazole | 23 | $5,983 |
| Tenofovir Disoproxil Fumarate | 46 | $5,558 |
| Mycophenolate Mofetil | 69 | $4,644 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 74 | $4,514 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 30 | $4,224 |
| Entecavir | 23 | $4,107 |
| Colestipol Hcl | 69 | $2,534 |
| Esomeprazole Magnesium | 51 | $2,252 |
| Pantoprazole Sodium | 263 | $2,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $292 | $177,844102 claims |
| Madrigal PharmaceuticalsRezdiffra | $27,176 | $75,63113 claims |
| AbbVieLinzess | $68,266 | $51,64457 claims |
| Braintree Laboratories, Inc.Sutab | $35 | $6,25439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cincinnati
- Anita AfzaliCincinnati$798K
- Kara de FeliceCincinnati$427K
- Allan PeckCincinnati$391K
- Robert IsfortCincinnati$162K
- Luis LaraCincinnati$146K
- Vidhya KunnathurCincinnati$96K
- Moamen GabrCincinnati$70K
- Lisa LestinaCincinnati$59K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.